We are pleased to announce our participation in the upcoming seventh edition of the Immunotherapies & Innovations for Infectious Diseases Congress (I4ID 2023), which will be held in Lyon, France on November 22-23, 2023.
Our team at Voxcan will be joining forces with Novaxia, both part of the ERBC Group, and will be waiting for you at booth 11, to discuss the opportunity to forge a new partnership that will accelerate your candidates’ time-to-market.
We cordially invite you to attend our oral presentation on November 23rd, during the Breakthrough Innovation session starting at 2 PM on “Recombinant multimeric spike proteins: A promising vaccine against COVID-19”. Our expert, Marianne Figl, PhD in virology, cellular and molecular biology, study director, infectious disease department, Voxcan, ERBC Group will discuss how we are fully engaged in the fight against COVID-19, how we have conducted more than 35 studies in small animal models (K18-hACE mice and Syrian golden hamsters), and how this research provides hope for an effective vaccine adapted and specific to new circulating strains of SARS-CoV-2 rapidly, based on a rational structure-based design with the potential for broader SARS-CoV-2 variant activity.
Our team Julia Matonti, Business Development Manager, Voxcan, ERBC Group, and Françoise Horand, Director Alliance Manager, ERBC Group are looking forward to meeting you and discussing our comprehensive range of preclinical services.